Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARION

Next Previous
Trial Profile

Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARION

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Fingolimod
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms CLARION
  • Sponsors Merck KGaA

    • Most Recent Events

    • 01 Jul 2022 Patients characteristics and design published in the Current Medical Research and Opinion
    • 25 Aug 2021 Results assessing data quality over time in MS registries participating in CLARION through the use of pre-defined DQIspresented at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 22 Jun 2021 Results (n=337) of a sub-group analysis reporting visits distribution, compliance with cladribine tablets dosing before and during pandemic in patients with multiple sclerosis from a german cohort presented at the 7th Congress of the European Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top